AlphaCrest Capital Management’s United Therapeutics UTHR Stock Holding History

AlphaCrest Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,879	Closed	-$603K	–	1092
2022 Q3	$603K	Sell	2,879 -3,522	-55%	-$787K	0.04%	895
2022 Q2	$1.51M	Buy	6,401 +718	+13%	+$146K	0.07%	471
2022 Q1	$1.02M	Sell	5,683 -2,313	-29%	-$441K	0.06%	538
2021 Q4	$1.73M	Sell	7,996 -2,606	-25%	-$512K	0.06%	506
2021 Q3	$1.96M	Buy	10,602 +4,289	+68%	+$845K	0.1%	312
2021 Q2	$1.13M	Buy	+6,313	New	+$1.2M	0.05%	600
2020 Q4	–	Sell	-2,529	Closed	-$255K	–	1281
2020 Q3	$255K	Sell	2,529 -3,101	-55%	-$340K	0.03%	950
2020 Q2	$681K	Sell	5,630 -4,417	-44%	-$497K	0.11%	259
2020 Q1	$953K	Buy	10,047 +4,469	+80%	+$425K	0.12%	296
2019 Q4	$491K	Sell	5,578 -19,552	-78%	-$1.72M	0.04%	795
2019 Q3	$2M	Buy	25,130 +3,287	+15%	+$265K	0.12%	236
2019 Q2	$1.71M	Buy	21,843 +16,294	+294%	+$1.52M	0.15%	194
2019 Q1	$651K	Buy	+5,549	New	+$647K	0.1%	362

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's UTHR Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of United Therapeutics (UTHR) in Q4 2022, closing a stake of 2,879 shares — an estimated $603K sold.

AlphaCrest Capital Management first reported a position in UTHR in Q1 2019 and held it in 13 quarters. The position peaked at $2M in Q3 2019. 512 funds tracked by Wall St. Rank hold UTHR as of Q4 2022.

AlphaCrest Capital Management reported no remaining United Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 2,879 United Therapeutics shares in Q4 2022, an estimated $603K.
AlphaCrest Capital Management first reported a position in United Therapeutics in Q1 2019 and held it in 13 quarters.
AlphaCrest Capital Management's United Therapeutics position peaked at $2M in Q3 2019.
512 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.